Table of Contents

• Trial overview
• Who can take part
• Study design and treatment
• What the study measures
• Trial phase and status
• Why this research matters

Trial overview

The available trial data describe one interventional study of ROPINIROLE in healthy volunteers.^[1] The study is designed to test whether a single oral dose changes metacognition and resting-state functional brain connectivity.^[1]

The trial title and summary show that the main focus is not a disease treatment study, but a mechanistic study of how ROPINIROLE may affect self-monitoring and brain network activity in people without a known illness.^[1]

Who can take part

The target population is healthy adults, described in the trial as healthy volunteers.^[1] The study does not list a disease group, so it is aimed at understanding the drug’s effect in people without the condition being studied.^[1]

The enrollment goal is 20 participants, which means this is a small study.^[1] Small studies like this are often used to explore a question before larger studies are done.^[1]

Study design and treatment

This is an interventional trial, meaning the researchers give a study treatment and then measure the effect.^[1] The intervention includes placebo and ROPINIROLE 1 mg given by mouth as a single dose.^[1]

Placebo is a look-alike treatment with no active study drug, and it is used to compare results fairly.^[1] The trial compares ROPINIROLE with placebo to see whether the drug changes confidence, accuracy, and brain connectivity.^[1]

What the study measures

The primary endpoint is the within-participant change in metacognitive efficiency, also called the M-ratio, under ROPINIROLE versus placebo.^[1] This is measured from confidence ratings during cognitive testing and uses a signal-detection-theoretic framework, which helps separate self-judgment from task performance.^[1]

The study uses a modified version of the Rey Auditory-Verbal Learning Test, which is a memory task that asks people to learn and recall words.^[1] Researchers use trial-by-trial accuracy and confidence ratings to see whether confidence matches actual performance.^[1]

The summary also says the study will look at metacognitive bias, meaning the gap between confidence and actual performance, and Goodman–Kruskal Gamma correlation, which shows how well confidence separates correct answers from errors.^[1] The brief summary states that the researchers want to know whether ROPINIROLE changes confidence without changing basic cognitive performance.^[1]

Trial phase and status

The trial is listed as Phase 4 and has the status Authorised.^[1] In the trial record, Phase 4 is linked with a product that already has marketing authorization and has been shown to be safe in humans.^[1]

Even though the product is already authorised, this study is still important because it asks a new research question about brain function and self-evaluation in healthy people.^[1]

Why this research matters

The trial summary explains that the researchers want to understand how dopaminergic stimulation may affect insight into one’s own performance.^[1] In simple terms, they are studying whether ROPINIROLE can make people more or less overconfident about their answers.^[1]

The study is also meant to help explain brain systems involved in self-awareness and unawareness of neurological disturbances, which is sometimes called anosognosia.^[1] The data suggest that findings from healthy volunteers may help guide future research on people who have problems with insight into their condition.^[1]

Table of Contents

• What is CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A?
• How does it work?
• What medical conditions can it treat?
• How is it administered?
• How effective is it?
• What are the potential side effects?
• Precautions and contraindications
• Ongoing research and future applications

What is CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A?

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS, also known as incobotulinumtoxinA or NT 201, is a purified form of botulinum toxin type A^[1]. It is a neurotoxin produced by the bacterium Clostridium botulinum, but it has been refined for medical use. This particular formulation is free of complexing proteins, which means it contains only the active neurotoxin without additional bacterial proteins^[2].

How does it work?

The neurotoxin works by temporarily blocking nerve signals to muscles, causing them to relax. Specifically, it prevents the release of a neurotransmitter called acetylcholine at the junction between nerves and muscles^[3]. This mechanism of action makes it useful for treating various conditions characterized by muscle overactivity or spasms.

What medical conditions can it treat?

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A is being studied for and used in the treatment of several medical conditions, including:

• Diabetic neuropathic pain: It is being investigated for treating pain in the lower limbs caused by diabetic neuropathy^[4].
• Chronic neuropathic pain: Studies are exploring its use in treating chronic pain due to nerve damage or injury^[5].
• Overactive bladder (OAB): It’s being tested as a treatment for OAB symptoms in women^[6].
• Lower limb spasticity: The neurotoxin is used to treat muscle stiffness and spasms in the legs, particularly in patients who have had a stroke or traumatic brain injury^[7].
• Temporomandibular disorders: Research is ongoing into its effectiveness for jaw pain and dysfunction^[8].
• Incisional hernia treatment: It’s being studied as a pre-operative treatment to relax abdominal muscles before hernia repair surgery^[9].

How is it administered?

The neurotoxin is typically administered through injection. The method of injection can vary depending on the condition being treated:

• For diabetic neuropathic pain, it may be injected around nerves in the legs^[4].
• In OAB treatment, it can be injected into the bladder wall using a special delivery system^[6].
• For spasticity, it’s injected directly into the affected muscles^[7].
• In temporomandibular disorders, it may be injected into jaw muscles^[8].

The dosage and frequency of administration can vary widely depending on the condition and individual patient factors. Always follow your healthcare provider’s instructions carefully.

How effective is it?

The effectiveness of CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A varies depending on the condition being treated. Clinical trials are ongoing to determine its efficacy for various uses. For example:

• In lower limb spasticity, it has shown promise in reducing muscle stiffness and improving range of motion^[7].
• For overactive bladder, studies are investigating its potential to reduce urinary incontinence episodes and improve quality of life^[6].
• In neuropathic pain conditions, research is exploring its ability to reduce pain intensity and improve daily functioning^[4][5].

What are the potential side effects?

As with any medical treatment, CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A can cause side effects. These can vary depending on the area of injection and the condition being treated. Some potential side effects include:

• Muscle weakness near the injection site
• Pain or bruising at the injection site
• Headache
• Fatigue
• Flu-like symptoms

In rare cases, the toxin’s effects may spread beyond the injection site, potentially causing more serious side effects like difficulty swallowing or breathing. It’s crucial to report any unusual symptoms to your healthcare provider immediately^[10].

Precautions and contraindications

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A is not suitable for everyone. It should not be used in patients with:

• Known allergies to botulinum toxin products
• Infection at the proposed injection site
• Certain neuromuscular disorders (e.g., myasthenia gravis)

Pregnant or breastfeeding women should consult their healthcare provider before using this treatment. Additionally, it may interact with certain medications, particularly those that affect neuromuscular function^[11].

Ongoing research and future applications

Research into new applications for CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A is ongoing. Current areas of investigation include:

• Its potential use in treating chronic migraine headaches
• Applications in cosmetic procedures
• Its role in managing various types of chronic pain

As research progresses, we may see this versatile neurotoxin being used to treat an even wider range of medical conditions in the future^[12].

The purpose of this study is to determine whether a single dose of ropinirole changes metacognitive performance in healthy adults and to understand how brain chemistry affects self-awareness and the ability to monitor one’s own thinking. Participants will receive either ropinirole or placebo on different occasions, and they will complete cognitive tasks that test memory and thinking while rating how confident they are in their answers. The study will measure whether the medication makes people feel more or less confident compared to their actual performance and whether it affects their ability to distinguish correct answers from incorrect ones.

During the study, participants will undergo brain imaging using resting-state fMRI, which is a type of scan that shows how different parts of the brain communicate with each other when a person is not performing any specific task. The researchers will look at specific brain networks including the Default Mode Network and Salience Network to see if ropinirole changes the connections between brain regions. Each participant will take part in sessions where they receive either the medication or placebo, complete cognitive tests with confidence ratings, and have brain scans to examine how the drug affects both brain activity and the ability to judge one’s own performance.

The study will evaluate different doses of azithromycin given as an oral suspension to determine its effects on cellular aging markers. The maximum daily dose will be 500 mg, and the treatment period will last up to three months. The research aims to find the most effective dose that could influence the aging process of cells.

During the study, researchers will examine blood samples to measure the levels of specific proteins and other substances that indicate cellular aging and inflammation. This will help determine how the medication affects the natural aging process at the cellular level. The study will also monitor the safety of using azithromycin for this purpose.

The purpose of the study is to evaluate how satisfied participants are with the results of the treatment. Participants will receive either the actual treatment or a placebo, which is a substance with no active ingredients. The study will compare the satisfaction levels of those who receive the treatment with those who receive the placebo. The treatment will be administered in split doses, meaning it will be given in smaller amounts but more frequently than usual.

Participants will be involved in the study for a period of time, during which they will receive the treatment and attend follow-up visits. The main focus will be on the change in satisfaction from the beginning of the study to two months after the last treatment. The study will also monitor any adverse events, which are any unexpected or negative reactions to the treatment. The goal is to understand the overall satisfaction with the treatment and its safety.

The purpose of the study is to see if switching from anticalcineurins to Belatacept can improve the function of blood vessels in kidney transplant patients over a period of six months. Blood vessels are important for carrying blood throughout the body, and their ability to widen and narrow properly is a sign of good health. The study will involve regular check-ups and tests to monitor the health of the blood vessels and overall well-being of the participants.

Participants in the study will be divided into two groups. One group will continue their current treatment with anticalcineurins, while the other group will switch to Belatacept. The study will last for several months, during which time participants will receive their assigned treatment and undergo various assessments to track changes in their blood vessel function. The results will help determine if Belatacept offers any advantages over anticalcineurins in maintaining healthy blood vessels in kidney transplant patients.

The purpose of this research is to evaluate whether medium to high doses of psilocybin therapy are safe and effective in reducing depression symptoms compared to low doses in patients with these conditions. Participants will receive two doses of the medication during the study, with evaluations of their depression symptoms occurring before treatment and six weeks after the second dose.

During the study, patients will be monitored for changes in their psychological well-being, including their ability to cope with end-of-life concerns, overall quality of life, and general mental health. The study will also look at how the treatment affects the stress levels and daily responsibilities of those caring for the patients. The treatment period will last approximately two months, with follow-up evaluations to track the participants’ progress.

The purpose of the study is to see if using the GnRH agonist alone can increase the chances of a live birth compared to the standard method. Participants in the study will receive one of these treatments and will be monitored throughout their IVF or ICSI cycle. The study will track various outcomes, including the rate of live births, the success of embryo implantation, and the occurrence of any pregnancy-related conditions. The medications involved in the study include progesterone, follitropin beta, follitropin alfa, ganirelix, nafarelin, triptorelin, choriogonadotropin alfa, and cetrorelix.

Participants will be given these medications in various forms, such as injections or nasal sprays, depending on the specific treatment protocol they are assigned to. The study aims to provide valuable information on the effectiveness and safety of these treatments in improving the chances of a successful pregnancy and live birth for individuals undergoing IVF or ICSI. The trial will continue until 2027, with the goal of gathering comprehensive data to inform future fertility treatments.

The purpose of the study is to evaluate how effective and safe Mirabegron is for treating symptoms of an overactive bladder in young children with a neurological cause. The study will also look at how long the medication stays in the body. Participants will receive the medication in gradually increasing doses, followed by a period where they receive a fixed dose. The study will last for up to 52 weeks, during which the children will be monitored for any changes in their condition and any side effects they might experience.

Throughout the study, various tests and observations will be conducted to assess the medication’s impact. These include checking bladder function, monitoring for any leakage episodes, and evaluating the overall acceptability of the treatment. The study will also involve regular health checks, such as vital signs and laboratory tests, to ensure the safety of the participants. The results will help determine if Mirabegron is a suitable treatment option for young children with Neurogenic Detrusor Overactivity.

Table of Contents

• Trial overview
• Breast cancer studies
• Prostate cancer studies
• Fertility and reproductive studies
• Other studies
• Main endpoints being measured
• Who can participate

Trial overview

The trial data show that Triptorelin is being studied in several different settings, mainly breast cancer, prostate cancer, and fertility treatment.^[1][2] Most studies are Phase 2 or Phase 3 trials, which means they are testing how well the treatment works in larger patient groups and, in some studies, comparing it with other options.^[1][2] Several studies are authorised, some are completed, and one study in the source data is withdrawn.^[1]

Breast cancer studies

Many Triptorelin trials focus on women with ER-positive/HER2-negative or HR-positive/HER2-negative early breast cancer, including both premenopausal and high-risk groups.^[2][3] In these studies, Triptorelin is used with other endocrine treatments, and the trials aim to see whether the treatment plan lowers cancer growth, delays recurrence, or improves invasive breast cancer-free survival.^[2][3]

One Phase 2 study in premenopausal women with operable breast cancer compared giredestrant plus Triptorelin with anastrozole plus Triptorelin, and also looked at giredestrant without Triptorelin.^[2] Its main endpoint was the change in Ki-67, a marker that shows how fast tumor cells are growing, measured between a biopsy before treatment and a biopsy after treatment.^[2]

Large Phase 3 trials also study Triptorelin in early breast cancer, including studies of adjuvant endocrine-based therapy and personalized treatment strategies in young women.^[3][4] These trials measure outcomes such as IBCFS, which is the time until an invasive breast cancer event, a new cancer in the other breast, or death.^[3][4]

Another completed Phase 2 study in metastatic breast cancer compared alpelisib-fulvestrant with ribociclib-fulvestrant in patients with persistent PIK3CA mutations after early treatment with a CDK4/6 inhibitor and fulvestrant.^[5] Triptorelin was one of the hormone treatment options listed in that study, and the main endpoint was progression-free survival.^[5]

Prostate cancer studies

Triptorelin is also studied often in prostate cancer, including localised, locally advanced, recurrent, oligometastatic, and metastatic disease.^[6][7] These studies usually compare different hormone treatment strategies, sometimes together with radiotherapy, and they look at whether the cancer stays controlled for longer or whether the risk of metastasis is reduced.^[6][7]

In a Phase 3 study of very high-risk localised or locally advanced prostate cancer, Triptorelin was one of several GnRH agonists compared with other hormone options alongside radiotherapy.^[6] The main endpoint was the proportion of patients reaching a PSA nadir below 0.1 ng/mL within 6 months after radiotherapy, which means the lowest PSA level achieved after treatment.^[6]

Another Phase 3 study looked at patients with oligorecurrent hormone-sensitive prostate cancer and tested whether adding short-term hormone therapy, including Triptorelin, to metastasis-directed therapy could delay poly-metastatic progression.^[7] That study measured poly-metastatic free survival, which is the time until the disease spreads to more than five new lesions on imaging or until treatment changes because of progression.^[7]

Other prostate cancer trials included Triptorelin in studies of salvage radiotherapy after surgery, darolutamide with or without radiation, and treatment approaches for metastatic castration-sensitive or castration-resistant disease.^[8][9] These studies measure outcomes such as metastasis-free survival, radiographic progression-free survival, biochemical disease-free survival, and quality of life.^[8][9]

Fertility and reproductive studies

Several Triptorelin trials are in fertility care, especially ovarian stimulation, embryo development, and fertility preservation.^[10][11] These studies involve women undergoing IVF, ICSI, oocyte donation, or planned fertility preservation, and they compare different stimulation or triggering approaches.^[10][11]

In ovarian stimulation studies, the main outcomes often focus on the number of MII oocytes, which are mature egg cells, or the number of good-quality blastocysts, which are early embryos with good development.^[10][11] For example, one Phase 3 trial compared intranasal nafarelin with subcutaneous Triptorelin to trigger final oocyte maturation, and another study compared different stimulation intensities in women undergoing PGT-A with a PPOS protocol.^[10][11]

Other fertility trials looked at live birth, clinical pregnancy, or the number of cumulus-oocyte complexes, which are egg cells surrounded by supporting cells collected after stimulation.^[12][13] One study also examined whether a GnRH agonist before frozen embryo transfer improves pregnancy rates in patients with endometriosis and/or adenomyosis.^[12]

There is also a Phase 3 study in women with low ovarian reserve and androgen receptor polymorphism that tested whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes after ovarian stimulation.^[13] This study was withdrawn in the source data, but it still shows the type of fertility questions being studied alongside Triptorelin.^[13]

Other studies

Triptorelin appears in a Phase 2 menopause study that compared a GnRH analog, transdermal estrogen, transdermal testosterone, and placebo over 8 weeks in postmenopausal women.^[14] The main outcome was the change in bone remodeling, measured through bone markers from baseline to week 8.^[14]

Another study looked at the use of Triptorelin in a Phase 1/II metastatic breast cancer trial combining [177Lu]Lu-NeoB with capecitabine, where Triptorelin was one of several hormone-related treatment options listed in the source data.^[15] The Phase I part focused on safety, dose-limiting toxicities, and tolerability, while the Phase II part looked at tumor response, clinical benefit, time to response, duration of response, progression-free survival, and overall survival.^[15]

Main endpoints being measured

The trial data show a wide range of endpoints, depending on the condition being studied.^[1] In cancer trials, common endpoints include survival without recurrence, progression-free survival, metastasis-free survival, PSA response, and changes in tumor markers such as Ki-67.^[2][6][8]

In fertility trials, the main endpoints often include the number of mature eggs, embryo quality, pregnancy rate, and live birth.^[10][11][12] In menopause research, the outcome is linked to bone marker changes, which help show how bone is being broken down or rebuilt.^[14]

Who can participate

Participation depends on the study and the disease being treated.^[1] The source data include premenopausal women with early or metastatic breast cancer, men with prostate cancer at different stages, women undergoing IVF or oocyte donation, postmenopausal women, and patients with endometriosis or adenomyosis.^{[2][6][10][12]}

Many studies have extra entry rules, such as hormone receptor status in breast cancer, the number of metastases in prostate cancer, or ovarian reserve in fertility trials.^[3][7][13] This means the trials are aimed at specific patient groups, not at everyone who uses Triptorelin in routine care.^[1]